Orchestra Biomed Holdings Stock Today
| OBIO Stock | 5.58 0.24 4.12% |
Performance1 of 100
| Odds Of DistressLess than 24
|
Orchestra BioMed is selling at 5.58 as of the 4th of December 2024; that is 4.12% down since the beginning of the trading day. The stock's open price was 5.82. Orchestra BioMed has about a 24 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Orchestra BioMed Holdings are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 4th of November 2024 and ending today, the 4th of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 4th of August 2020 | Category Healthcare | Classification Health Care |
Orchestra BioMed is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 37.82 M outstanding shares of which 754.3 K shares are now shorted by private and institutional investors with about 13.57 trading days to cover. More on Orchestra BioMed Holdings
Moving against Orchestra Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Orchestra Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman Founder | David Hochman | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsOrchestra BioMed can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Orchestra BioMed's financial leverage. It provides some insight into what part of Orchestra BioMed's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Orchestra BioMed Holdings (OBIO) is traded on NASDAQ Exchange in USA. It is located in 150 Union Square Drive, New Hope, PA, United States, 18938 and employs 56 people. Orchestra BioMed is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 221.24 M. Orchestra BioMed Holdings conducts business under Biotechnology sector and is part of Health Care industry. The entity has 37.82 M outstanding shares of which 754.3 K shares are now shorted by private and institutional investors with about 13.57 trading days to cover.
Orchestra BioMed generates negative cash flow from operations
Check Orchestra BioMed Probability Of Bankruptcy
Ownership AllocationOrchestra BioMed owns a total of 37.82 Million outstanding shares. Over half of Orchestra BioMed's outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Orchestra Ownership Details
Orchestra BioMed Historical Income Statement
Orchestra Stock Against Markets
Orchestra BioMed Corporate Management
| Yuval DSc | GM Therapies | Profile | |
| George Papandreou | Senior Therapies | Profile | |
| Avraham MD | Senior Innovation | Profile | |
| Andrew MBA | Chief Officer | Profile | |
| HansPeter MD | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Orchestra BioMed Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Orchestra BioMed. If investors know Orchestra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Orchestra BioMed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.60) | Revenue Per Share 0.073 | Quarterly Revenue Growth 1.356 | Return On Assets (0.39) | Return On Equity (0.92) |
The market value of Orchestra BioMed Holdings is measured differently than its book value, which is the value of Orchestra that is recorded on the company's balance sheet. Investors also form their own opinion of Orchestra BioMed's value that differs from its market value or its book value, called intrinsic value, which is Orchestra BioMed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Orchestra BioMed's market value can be influenced by many factors that don't directly affect Orchestra BioMed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Orchestra BioMed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Orchestra BioMed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orchestra BioMed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.